[1]夏 丽,陈 洁,李 秀.慢性阻塞性肺疾病频繁急性加重患者的临床特征分析[J].医学信息,2019,32(23):100-103.[doi:10.3969/j.issn.1006-1959.2019.23.027]
　XIA Li,CHEN Jie,LI Xiu.Clinical Characteristics of Patients with Chronic Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,32(23):100-103.[doi:10.3969/j.issn.1006-1959.2019.23.027]
点击复制

慢性阻塞性肺疾病频繁急性加重患者的临床特征分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年23期
页码:
100-103
栏目:
论著
出版日期:
2019-12-01

文章信息/Info

Title:
Clinical Characteristics of Patients with Chronic Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2019）23-0100-04
作者:
夏 丽; 陈 洁; 李 秀
（安徽医科大学第三附属医院呼吸内科，安徽 合肥 230000）
Author(s):
XIA Li; CHEN Jie; LI Xiu
(Department of Respiratory Medicine,the Third Affiliated Hospital of Anhui Medical University,Hefei 230000,Anhui,China)
关键词:
慢性阻塞性肺疾病; 频繁急性加重; 呼吸衰竭; 肺功能
Keywords:
Chronic obstructive pulmonary disease; Frequent acute exacerbation; Respiratory failure;  Pulmonary function
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2019.23.027
文献标志码:
A
摘要:
目的 观察慢性阻塞性肺疾病（COPD）频繁急性加重患者与非频繁急性加重患者临床特征的差异。方法 回顾性纳入2016年1月~2018年12月合肥市第一人民医院呼吸内科住院的274例COPD急性加重患者，根据患者上一年急性加重次数分为频繁组（住院次数≥2次/年）143例和非频繁组（住院次数＜2次/年）131例，比较两组性别、年龄、病程、吸烟量、mMRC评分、共患疾病（高血压、冠心病、糖尿病）、白细胞计数、中性粒细胞百分比、淋巴细胞百分比、嗜酸粒细胞百分比、降钙素原（PCT）、血气指标（pH、PaO2、PaCO2）及血氧饱和度（SpO2），多因素Logistic回归分析COPD频繁急性加重的危险因素。结果 两组性别、年龄、白细胞计数、淋巴细胞百分比、嗜酸粒细胞百分比、PCT、pH、PaCO2、共患疾病（高血压、冠心病、糖尿病）比较，差异无统计学意义（P＞0.05）；频繁组病程、吸烟量、mMRC评分、中性粒细胞百分比、SpO2、PaO2均高于非频繁组，差异均有统计学意义（P＜0.05）；多因素Logistic回归分析显示，病程、吸烟量、mMRC评分、中性粒细胞百分比是COPD频繁急性加重的独立危险因素。结论 COPD频繁急性加重多病程较长，患者多长期吸烟，临床中应重视病程长、吸烟量大、mMRC评分高、中性粒细胞百分比高的COPD患者，加强对其的监护管理，防止发生COPD频繁急性加重。
Abstract:
Objective To observe the clinical features of patients with frequent exacerbation of chronic obstructive pulmonary disease (COPD) and patients with infrequent acute exacerbations. Methods Retrospectively included 274 patients with acute exacerbations of COPD who were admitted to the Department of Respiratory Medicine of Hefei First People’s Hospital from January 2016 to December 2018.According to the number of patients with acute exacerbations in the previous year, 143 patients in the frequent group (number of hospitalizations ≥ 2 times / year) and 131 patients in the non-frequent group (number of hospitalizations < 2 times / year) were compared. Compare gender, age, duration of disease, smoking, mMRC score, comorbidity (hypertension, coronary heart disease, diabetes), white blood cell count, percentage of neutrophils, percentage of lymphocytes, percentage of eosinophils, calcium reduction prime factors (PCT), blood gas indicators (pH, PaO2, PaCO2) and oxygen saturation (SpO2), multivariate Logistic regression analysis of risk factors for frequent acute exacerbations of COPD.Results There were no significant differences in gender, age, white blood cell count, percentage of lymphocytes, percentage of eosinophils, PCT, pH, PaCO2, comorbidity (hypertension, coronary heart disease, diabetes) between the two groups (P>0.05). The frequent course, smoking, mMRC score, neutrophil percentage, SpO2, PaO2 were higher than the non-frequent group, the difference was statistically significant (P<0.05); multivariate Logistic regression analysis showed that the course of disease, smoking,the mMRC score and the percentage of neutrophils are independent risk factors for frequent acute exacerbations of COPD.Conclusion Frequent acute exacerbation of COPD has a long course of disease. Patients with long-term smoking should pay attention to patients with COPD who have long course of disease, high smoking, high score of mMRC and high percentage of neutrophils in clinical practice, strengthen the monitoring and management of it to prevent frequent acute exacerbations of COPD.

参考文献/References:

[1]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH] study):a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.[2]Pauwels RA,Buist AS,Calverley PM,et al. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease.NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease(GOLD)Workshop summary[J].Am J Respir Crit Care Med,2001,163(5):1256-1276.[3]Capozzolo A,Carratù P,Dragonieri S,et al.Clinical and Functional lung Parameters associated with frequent exacerbator phenotype in subjects with severe COPD[J].Respire Care,2017,62(5):572-578.[4]Gulati S,Wells JM.Bringing stability to the chronic obstructive pulnonary disease patient:Clinical and pharmacological considerations for frequent exacebators[J].Drugs,2017,77(6):651-670.[5]Karoli NA,Rebrov AP.Sudden cardiac death in patients with chronic obstructive Pulmonary disease[J].Kardiologiia,2017,57(2):83-90.[6]Molinari N,Briand C,Vachier I,et al.Hospitalizations for COPD exacerbations:Trends and determinants of death[J].COPD,2015,12(6):621-627.[7]Kourlaba G,Hillas G,Vassilakopoulos T,et al.The Economic burden of chronic obstructive pulmonary disease in Greece[J].Springer Nature Switzerl and AG,2019,17(1):111-121.[8]Cao Z,Ong KC,Eng P,et al.Frequent hospital readmissions for acute exacerbation of COPD and their associated factors[J].Respirology,2006,11(2):188-195.[9]Fletcher C,Peto R.The natural history of chronic airflow obstruction[J].Br Med J,1997(1):1645-1648.[10]Donaldson GC,Seemunggal TA,Bhowmik A,et al.Relationship between exacerbation frequency and lung fuction decline in chronic obstructive pulmonary disease[J].Original Article,Thorax 2002,57(10):847-852.[11]Tal S,Adir Y,Stein N,et al.COPD exacerbator phenotype is inversely associated with current smoking but not with haptoglobin phenotype[J].Isr Med Assoc J,2019,21(1):19-23.[12]Au DH,Bryson CL,Chien JW,et al.The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations[J].Gen Intern Med,2009,24(4):457-463.[13]袁义,杨刚.慢性阻塞性肺疾病评估测试在急性加重期的研究[J].临床肺科杂志,2014,19(5):807-809.[14]Cheng Y,Tu X,Pan L,et al.Clinical characteristics of chronic bronchitic,emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations[J].International Journal of COPD,2017(12):2069-2074.[15]Lee SJ,Lee SH,Kim YE,et al.Clinical Features according to the Frequency of Acute Exacerbation in COPD[J].Tuberc Respir Dis(Seoul),2012,72(4):367-373. [16]蒋雪莲,钟萍,黄成亮,等.氧化应激反应标志物在慢性阻塞性肺疾病稳定期患者血清中的表达和意义[J].中国呼吸与危重监护杂志,2016,15(6):542-547.[17]Günay E,Sarinc Ulasli S,et al.Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease：a retroapective study[J].Inflammation,2014,37(2):374-380.[18]Bhowmik A,Seemugal TA,Sapsford RJ,et al.Relation of sputum inflammation makers to symptoms and lung fuction changes in COPD exacerbations[J].Thorax, 2000,55(2):114-120. [19]Lee H,Um SJ,Kim YS,et al.Association of the Neutrophil-to-Lymphocyte Ratio with Lung Function and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease[J].PLoS One,2016,11(6):e0156511.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(23):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(23):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(23):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(23):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 2019-12-01